Vapotherm (VAPO) Tops Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St to open lower as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Oppenheimer sees AI software winners as focus shifts to ROI
- Nvidia releases AI safety software it says could have stopped Hugging Face hack
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
Vapotherm Reports First Quarter 2019 Financial Results
May 7, 2019 4:01 PM EDTEXETER, N.H.--(BUSINESS WIRE)-- Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced its financial and operating results for the first quarter ended March 31, 2019.
First Quarter 2019 Summary
Revenue for the first quarter of 2019 was $12.3 million, representing a 14.5% increase over the prior year period Gross margin was 42.1% in comparison to gross margin of 39.5% in the first... More